The significant outperformance of Ascendis Pharma compared to the market, as evidenced by its 28.88% average annual return over 15 years, suggests a strong growth trajectory and operational success. This historical performance, coupled with a current market capitalization of $7.77 billion, indicates a positive outlook for the company's stock in the short term, assuming market conditions remain favorable and the company continues on its growth path.